| Literature DB >> 30738958 |
Alessio Buonavoglia1, Patrizia Leone1, Rosanna Dammacco2, Giuseppe Di Lernia1, Massimo Petruzzi3, Domenico Bonamonte4, Angelo Vacca1, Vito Racanelli5, Franco Dammacco6.
Abstract
Pemphigus diseases (PDs) and mucous membrane pemphigoid (MMP) are a group of immune-mediated mucocutaneous disorders clinically characterized by the formation of blisters, erosions and ulcers. The skin and mucous membranes are predominantly affected, with the oropharyngeal mucosa as the initially involved site. Ocular involvement is also a frequent feature of these diseases. Because of the considerable overlap in their clinical presentations, the diagnosis of PDs vs. MMP can be challenging. A recognition of their specific immunological and histopathologic features is crucial in the differential diagnosis. Treatment modalities include systemically administered corticosteroids, steroid-sparing immunosuppressive agents, and biologic therapies (rituximab, intravenous immunoglobulins, and anti-tumor necrosis factor agents). Topical, oral, conjunctival, or intralesional corticosteroids as well as anti-inflammatory drugs and antibiotics are prescribed as needed.Entities:
Keywords: Autoimmune blistering diseases; Cicatricial pemphigoid; Corticosteroids; Desmoglein-1; Desmoglein-3; Immunosuppressive drugs; Pemphigus vulgaris
Mesh:
Substances:
Year: 2019 PMID: 30738958 DOI: 10.1016/j.autrev.2019.02.005
Source DB: PubMed Journal: Autoimmun Rev ISSN: 1568-9972 Impact factor: 9.754